Avances en el tratamiento de la fibrosis quística: los moduladores de la CFTR
Resumen: La fibrosis quística es una enfermedad genética y grave causada por variantes en el gen CFTR. Aunque se trata de una enfermedad multisistémica, la afectación respiratoria es la que produce mayor morbimortalidad. Los moduladores de CFTR (CFTRm) han supuesto un avance terapéutico al mejorar l...
Saved in:
| Main Authors: | Maria Dolores Pastor-Vivero, Jordi Costa i Colomer, Carlos Martín de Vicente, Saioa Vicente-Santamaria, Ruth García Romero, David González Jiménez, Carmen Luna Paredes |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Elsevier
2025-05-01
|
| Series: | Anales de Pediatría |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S169540332500092X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advances in the treatment of cystic fibrosis: CFTR modulators
by: Maria Dolores Pastor-Vivero, et al.
Published: (2025-05-01) -
Effect of CFTR modulators on glucose homeostasis in children and young adults with cystic fibrosis-related diabetes: a systematic review
by: Paola Giordano, et al.
Published: (2025-08-01) -
Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction
by: Alice Castaldo, et al.
Published: (2025-07-01) -
Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real‐World Evidence From an Italian Single‐Center Study
by: Nicola Perrotta, et al.
Published: (2025-04-01) -
Heightened mitochondrial respiration in CF cells is normalised by triple CFTR modulator therapy through mechanisms involving calcium
by: H.H. Jarosz-Griffiths, et al.
Published: (2024-10-01)